CureVac teams up with Bayer to accelerate development of Covid vaccine

Germany’s CureVac has teamed up with the country’s largest pharmaceuticals company Bayer to accelerate the development and production of its Covid-19 vaccine. The Tübingen-based company, whose vaccine uses a similar technology to the ones developed by BioNTech and Moderna, said on Thursday it had entered into a collaboration and services agreement that would help it deliver several hundred million doses. CureVac, the oldest of the trio of companies working on messenger RNA technology to develop vaccines, was among the first to announce it was working on a product to deal with Sars-Cov-2, the virus that causes Covid-19. But it has since lagged far behind its competitors, both of which have already won authorisations in the US and EU.